Nanosuspension formulation for treatment of pulmonary fibrosis
AssigneesThe Johns Hopkins University, Federal University of Rio De Janeiro
InventorsJung Soo Suk, Luisa Helena Andrade Da Silva, Patricia Rocco, Marcelo Morales
Life of this patent
Estimating the term…
Abstract
An inhalable nanocrystal-based suspension formulation of nintedanib (NTB) (NTB-NS) possessing specific physicochemical properties to enhance drug retention in the lung was developed for localized treatment of pulmonary fibrosis via inhalation. This NTB-NS formulation was prepared using a wet-milling procedure in the presence of a surfactant, PLURONIC® F127, to endow the formulation with non-adhesive surface coatings to minimize interactions with therapy-inactivating delivery barriers in the lung.
Claims20
A formulation for administration to the lungs of an individual in need of treatment of pulmonary fibrosis comprising:
- comprising coated nanocrystals, wherein the nancocrystals are formed of an anti-fibrotic kinase inhibitor, and the coating is formed from a non-ionic surfactant, wherein the coated nanocrystals are between 50 nm and 500 nm in diameter.
A kit comprising:
- (i) a formulation comprising coated nanocrystals,
- wherein the coated nanocrystals comprise:
- (a) nanocrystals formed of an anti-fibrotic kinase inhibitor and
- (b) a coating formed of a non-ionic surfactant,
- wherein the coated nanocrystals are between 50 nm and 500 nm in diameter;
- and
- (ii) a liquid carrier,
- wherein the formulation and liquid carrier are packaged separately.
Dependencies are inferred from the claim text.